APLS
Price
$17.43
Change
-$0.97 (-5.27%)
Updated
Jun 27 closing price
Capitalization
2.19B
44 days until earnings call
CRBP
Price
$7.40
Change
-$0.62 (-7.73%)
Updated
Jun 27 closing price
Capitalization
91.65M
Interact to see
Advertisement

APLS vs CRBP

Header iconAPLS vs CRBP Comparison
Open Charts APLS vs CRBPBanner chart's image
Apellis Pharmaceuticals
Price$17.43
Change-$0.97 (-5.27%)
Volume$3.83M
Capitalization2.19B
Corbus Pharmaceuticals Holdings
Price$7.40
Change-$0.62 (-7.73%)
Volume$1.39M
Capitalization91.65M
APLS vs CRBP Comparison Chart in %
Loading...
APLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CRBP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
APLS vs. CRBP commentary
Jun 28, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is APLS is a Hold and CRBP is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 28, 2025
Stock price -- (APLS: $17.43 vs. CRBP: $7.49)
Brand notoriety: APLS and CRBP are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: APLS: 130% vs. CRBP: 754%
Market capitalization -- APLS: $2.19B vs. CRBP: $91.65M
APLS [@Biotechnology] is valued at $2.19B. CRBP’s [@Biotechnology] market capitalization is $91.65M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

APLS’s FA Score shows that 0 FA rating(s) are green whileCRBP’s FA Score has 0 green FA rating(s).

  • APLS’s FA Score: 0 green, 5 red.
  • CRBP’s FA Score: 0 green, 5 red.
According to our system of comparison, CRBP is a better buy in the long-term than APLS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

APLS’s TA Score shows that 3 TA indicator(s) are bullish while CRBP’s TA Score has 3 bullish TA indicator(s).

  • APLS’s TA Score: 3 bullish, 6 bearish.
  • CRBP’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, both APLS and CRBP are a bad buy in the short-term.

Price Growth

APLS (@Biotechnology) experienced а -1.47% price change this week, while CRBP (@Biotechnology) price change was -9.10% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.22%. For the same industry, the average monthly price growth was +31.37%, and the average quarterly price growth was +12.88%.

Reported Earning Dates

APLS is expected to report earnings on Aug 11, 2025.

CRBP is expected to report earnings on May 06, 2025.

Industries' Descriptions

@Biotechnology (+4.22% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
APLS($2.19B) has a higher market cap than CRBP($91.7M). CRBP YTD gains are higher at: -36.525 vs. APLS (-45.378). CRBP has higher annual earnings (EBITDA): -48.74M vs. APLS (-176.08M). APLS has more cash in the bank: 358M vs. CRBP (133M). CRBP has less debt than APLS: CRBP (2.86M) vs APLS (470M). APLS has higher revenues than CRBP: APLS (776M) vs CRBP (0).
APLSCRBPAPLS / CRBP
Capitalization2.19B91.7M2,389%
EBITDA-176.08M-48.74M361%
Gain YTD-45.378-36.525124%
P/E RatioN/AN/A-
Revenue776M0-
Total Cash358M133M269%
Total Debt470M2.86M16,462%
FUNDAMENTALS RATINGS
APLS vs CRBP: Fundamental Ratings
APLS
CRBP
OUTLOOK RATING
1..100
5957
VALUATION
overvalued / fair valued / undervalued
1..100
70
Overvalued
51
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9896
PRICE GROWTH RATING
1..100
6559
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CRBP's Valuation (51) in the Biotechnology industry is in the same range as APLS (70) in the Medical Distributors industry. This means that CRBP’s stock grew similarly to APLS’s over the last 12 months.

CRBP's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as APLS (100) in the Medical Distributors industry. This means that CRBP’s stock grew similarly to APLS’s over the last 12 months.

CRBP's SMR Rating (96) in the Biotechnology industry is in the same range as APLS (98) in the Medical Distributors industry. This means that CRBP’s stock grew similarly to APLS’s over the last 12 months.

CRBP's Price Growth Rating (59) in the Biotechnology industry is in the same range as APLS (65) in the Medical Distributors industry. This means that CRBP’s stock grew similarly to APLS’s over the last 12 months.

CRBP's P/E Growth Rating (100) in the Biotechnology industry is in the same range as APLS (100) in the Medical Distributors industry. This means that CRBP’s stock grew similarly to APLS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
APLSCRBP
RSI
ODDS (%)
N/A
Bearish Trend 1 day ago
74%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
73%
Momentum
ODDS (%)
Bearish Trend 1 day ago
76%
Bearish Trend 1 day ago
89%
MACD
ODDS (%)
Bearish Trend 1 day ago
66%
Bearish Trend 1 day ago
86%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
81%
Bearish Trend 1 day ago
90%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 1 day ago
85%
Advances
ODDS (%)
Bullish Trend 19 days ago
81%
Bullish Trend 4 days ago
80%
Declines
ODDS (%)
Bearish Trend 6 days ago
79%
Bearish Trend 6 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
76%
Bearish Trend 1 day ago
84%
Aroon
ODDS (%)
Bullish Trend 1 day ago
86%
Bullish Trend 1 day ago
82%
View a ticker or compare two or three
Interact to see
Advertisement
APLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CRBP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ABLZF59.552.92
+5.16%
ABB Ltd.
CNTMF0.05N/A
-0.20%
FLUENT CORP
BKKLY21.90-0.14
-0.64%
Bangkok Bank Public Co Ltd.
NVNXF0.25-0.01
-2.63%
NOVONIX Ltd.
ELEZY15.93-0.45
-2.72%
Endesa S.A.

APLS and

Correlation & Price change

A.I.dvisor indicates that over the last year, APLS has been loosely correlated with ROIV. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if APLS jumps, then ROIV could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To APLS
1D Price
Change %
APLS100%
-5.27%
ROIV - APLS
45%
Loosely correlated
-1.81%
BPMC - APLS
44%
Loosely correlated
-0.03%
RARE - APLS
44%
Loosely correlated
-2.46%
EYPT - APLS
44%
Loosely correlated
-6.94%
DNLI - APLS
43%
Loosely correlated
-2.77%
More

CRBP and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRBP has been loosely correlated with SKYE. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if CRBP jumps, then SKYE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRBP
1D Price
Change %
CRBP100%
-6.61%
SKYE - CRBP
47%
Loosely correlated
-2.33%
FBIO - CRBP
39%
Loosely correlated
-2.16%
STOK - CRBP
37%
Loosely correlated
-1.86%
APLS - CRBP
34%
Loosely correlated
-5.27%
PMCB - CRBP
30%
Poorly correlated
-2.86%
More